|
1
|
Sánchez-González C, Ciudad CJ, Noé V and
Izquierdo-Pulido M: Walnut polyphenol metabolites, urolithins A and
B, inhibit the expression of the prostate-specific antigen and the
androgen receptor in prostate cancer cells. Food Funct.
5:2922–2930. 2014.
|
|
2
|
Lewandowska U, Owczarek K, Szewczyk K,
Podsędek A, Koziołkiewicz M and Hrabec E: Influence of polyphenol
extract from evening primrose (Oenothera paradoxa) seeds on
human prostate and breast cancer cell lines. Postepy Hig Med Dosw
(Online). 68:110–118. 2014.
|
|
3
|
Stagos D, Amoutzias GD, Matakos A, Spyrou
A, Tsatsakis AM and Kouretas D: Chemoprevention of liver cancer by
plant polyphenols. Food Chem Toxicol. 50:2155–2170. 2012.
|
|
4
|
Di Domenico F, Foppoli C, Coccia R and
Perluigi M: Antioxidants in cervical cancer: Chemopreventive and
chemotherapeutic effects of polyphenols. Biochim Biophys Acta.
1822:737–747. 2012.
|
|
5
|
Abbas A, Patterson W III and Georgel PT:
The epigenetic potentials of dietary polyphenols in prostate cancer
management. Biochem Cell Biol. 91:361–368. 2013.
|
|
6
|
Haraguchi T, Kayashima T, Okazaki Y, Inoue
J, Mineo S, Matsubara K, Sakaguchi E, Yanaka N and Kato N: Cecal
succinate elevated by some dietary polyphenols may inhibit colon
cancer cell proliferation and angiogenesis. J Agric Food Chem.
62:5589–5594. 2014.
|
|
7
|
Lall RK, Syed DN, Adhami VM, Khan MI and
Mukhtar H: Dietary polyphenols in prevention and treatment of
prostate cancer. Int J Mol Sci. 16:3350–3376. 2015.
|
|
8
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011.
|
|
9
|
Siegel R, Miller KD and Jemal A: Cancer
statistics, 2015. CA: A Cancer Journal for Clinicians. 65:5–29.
2015.
|
|
10
|
Vargas-Hernández VM, Moreno-Eutimio MA,
Acosta-Altamirano G and Vargas-Aguilar VM: Management of recurrent
epithelial ovarian cancer. Gland Surg. 3:198–202. 2014.
|
|
11
|
Cohen JG, White M, Cruz A and
Farias-Eisner R: In 2014, can we do better than CA125 in the early
detection of ovarian cancer? World J Biol Chem. 5:286–300.
2014.
|
|
12
|
Kigawa J: New strategy for overcoming
resistance to chemotherapy of ovarian cancer. Yonago Acta Med.
56:43–50. 2013.
|
|
13
|
Ott I and Gust R: Non platinum metal
complexes as anti-cancer drugs. Arch Pharm (Weinheim). 340:117–126.
2007.
|
|
14
|
Ayyagari VN and Brard L: Bithionol
inhibits ovarian cancer cell growth in vitro - studies on
mechanism(s) of action. BMC Cancer. 14:612014.
|
|
15
|
Agarwal R and Kaye SB: Ovarian cancer:
Strategies for overcoming resistance to chemotherapy. Nat Rev
Cancer. 3:502–516. 2003.
|
|
16
|
Luo H, Jiang BH, King SM and Chen YC:
Inhibition of cell growth and VEGF expression in ovarian cancer
cells by flavonoids. Nutr Cancer. 60:800–809. 2008.
|
|
17
|
Luo H, Rankin GO, Juliano N, Jiang BH and
Chen YC: Kaempferol inhibits VEGF expression and in vitro
angiogenesis through a novel ERK-NFκB-cMyc-p21 pathway. Food Chem.
130:321–328. 2012.
|
|
18
|
Chen AY and Chen YC: A review of the
dietary flavonoid, kaempferol on human health and cancer
chemoprevention. Food Chem. 138:2099–2107. 2013.
|
|
19
|
Kuo CL, Lai KC, Ma YS, Weng SW, Lin JP and
Chung JG: Gallic acid inhibits migration and invasion of SCC-4
human oral cancer cells through actions of NF-κB, Ras and matrix
metal-loproteinase-2 and -9. Oncol Rep. 32:355–361. 2014.
|
|
20
|
You BR, Kim SZ, Kim SH and Park WH: Gallic
acid-induced lung cancer cell death is accompanied by ROS increase
and glutathione depletion. Mol Cell Biochem. 357:295–303. 2011.
|
|
21
|
Cedó L, Castell-Auví A, Pallarès V, Macià
A, Blay M, Ardévol A, Motilva MJ and Pinent M: Gallic acid is an
active component for the anticarcinogenic action of grape seed
procyanidins in pancreatic cancer cells. Nutr Cancer. 66:88–96.
2014.
|
|
22
|
Lu Y, Jiang F, Jiang H, Wu K, Zheng X, Cai
Y, Katakowski M, Chopp M and To SS: Gallic acid suppresses cell
viability, proliferation, invasion and angiogenesis in human glioma
cells. Eur J Pharmacol. 641:102–107. 2010.
|
|
23
|
Zhao B and Hu M: Gallic acid reduces cell
viability, proliferation, invasion and angiogenesis in human
cervical cancer cells. Oncol Lett. 6:1749–1755. 2013.
|
|
24
|
He Z, Li B, Rankin GO, Rojanasakul Y and
Chen YC: Selecting bioactive phenolic compounds as potential agents
to inhibit proliferation and VEGF expression in human ovarian
cancer cells. Oncol Lett. 9:1444–1450. 2015.
|
|
25
|
Jafari S, Saeidnia S and Abdollahi M: Role
of natural phenolic compounds in cancer chemoprevention via
regulation of the cell cycle. Curr Pharm Biotechnol. 15:409–421.
2014.
|
|
26
|
Carocho M and Ferreira IC: The role of
phenolic compounds in the fight against cancer - a review.
Anticancer Agents Med Chem. 13:1236–1258. 2013.
|
|
27
|
Manach C, Williamson G, Morand C, Scalbert
A and Rémésy C: Bioavailability and bioefficacy of polyphenols in
humans. I. Review of 97 bioavailability studies. Am J Clin Nutr.
81(Suppl 1): 230S–242S. 2005.
|
|
28
|
Roberts AT, Martin CK, Liu Z, Amen RJ,
Woltering EA, Rood JC, Caruso MK, Yu Y, Xie H and Greenway FL: The
safety and efficacy of a dietary herbal supplement and gallic acid
for weight loss. J Med Food. 10:184–188. 2007.
|
|
29
|
Yamamizu K, Furuta S, Hamada Y, Yamashita
A, Kuzumaki N and Narita M: Dio K, Katayama S, Nagase H, Yamashita
JK, et al κ opioids inhibit tumor angiogenesis by suppressing VEGF
signaling. Sci Rep. 3:32132013.
|
|
30
|
Huang KF, Yang HY, Xing YM, Lin JS and
Diao Y: Recombinant human kallistatin inhibits angiogenesis by
blocking VEGF signaling pathway. J Cell Biochem. 115:575–584.
2014.
|
|
31
|
Strathdee G, MacKean MJ, Illand M and
Brown R: A role for methylation of the hMLH1 promoter in loss of
hMLH1 expression and drug resistance in ovarian cancer. Oncogene.
18:2335–2341. 1999.
|
|
32
|
Luo H, Li B, Li Z, Cutler SJ, Rankin GO
and Chen YC: Chaetoglobosin K inhibits tumor angiogenesis through
downregulation of vascular epithelial growth factor-binding
hypoxia-inducible factor 1α. Anticancer Drugs. 24:715–724.
2013.
|
|
33
|
Mandl M, Kapeller B, Lieber R and Macfelda
K: Hypoxia-inducible factor-1β (HIF-1β) is upregulated in a
HIF-1α-dependent manner in 518A2 human melanoma cells under hypoxic
conditions. Biochem Biophys Res Commun. 434:166–172. 2013.
|
|
34
|
Li H, Zeng J and Shen K: PI3K/AKT/mTOR
signaling pathway as a therapeutic target for ovarian cancer. Arch
Gynecol Obstet. 290:1067–1078. 2014.
|
|
35
|
Park ST, Kim BR, Park SH, Lee JH, Lee EJ,
Lee SH and Rho SB: Suppression of VEGF expression through
interruption of the HIF 1α and Akt signaling cascade modulates the
anti angiogenic activity of DAPK in ovarian carcinoma cells. Oncol
Rep. 31:1021–1029. 2014.
|
|
36
|
Mao Y, Xu J, Song G, Zhang N and Yin H:
Twist2 promotes ovarian cancer cell survival through activation of
Akt. Oncol Lett. 6:169–174. 2013.
|
|
37
|
Dobbin ZC and Landen CN: The importance of
the PI3K/AKT/mTOR pathway in the progression of ovarian cancer. Int
J Mol Sci. 14:8213–8227. 2013.
|
|
38
|
Jiang BH and Liu LZ: PI3K/PTEN signaling
in angiogenesis and tumorigenesis. Adv Cancer Res. 102:19–65.
2009.
|
